Introduction {#sec1-1}
============

One of the most common cancers in women globally, breast cancer (BC) influences over 1 million women yearly (Keegan et al., 2007; Babu et al., 2011; Bray et al., 2013). The etiology of BC is unclear, but genetic factors have been suggested to play key functions in the development of BC (Hashemi et al., 2012a; Hashemi et al., 2012b; Hashemi et al., 2013a).

MiRNAs are small, non-coding, sequences of nucleotides that control gene expression through attaching to complementary sites in the 3'-untranslated region (3'UTRs) of target mRNAs (Meltzer, 2005). Till now, nearly 2000 miRNAs have been identified in humans and growing proof highlights their central function in the differentiation, cell propagation, carcinogenesis, tumour progression and response to treatment (Valeri et al., 2010). The lethal-7 (let-7) family members are among the most known miRNAs in human cancers. In general, they function as tumour suppressors by suppressing oncogenes implicated in the regulation of the cell cycle or intracellular signaling cascades (Su et al., 2012). The V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (*KRAS*) is an effector molecule that contributes to several important signal transduction pathways such as Ral guanine nucleotide exchange factor and mitogen-activated protein kinase, phosphatidylinositol 3-kinase pathways. *KRAS* is a recognized target of let-7 and multiple complementary sites for this miRNA were determined in the 3'-untranslated (3'UTR) region of the mRNA.

Recent work has introduced that a germline and functional single-nucleotide polymorphism (SNP) in the *KRAS* 3'UTR region (rs61764370 T/G) is located in the let-7 complementary site 6 (LCS-6). Current proof indicated that that LCS-6 disrupts the let-7 binding affinity for *KRAS*, and result in decreased *KRAS* inhibition and enhanced tumour growth (Johnson et al., 2007; Chung et al., 2014). A number studies have examined the impact of *KRAS* rs61764370 T/G polymorphism on the risk of various cancers. For example, the LCS6 variant allele was shown to affect non-small cell lung cancer (NSCLC) in moderate smokers (Chin et al., 2008), triple-negative BC in premenopausal women (Paranjape et al., 2011) and ovarian cancer in BRCA negative females from inherited BC and ovarian cancer syndrome families (Ratner et al., 2010).

Another SNP within *KRAS* gene is in the rs712 region of the let-7 binding site, which is another miRNA target site. A number studies have assessed the impact of rs712 genetic variation in different cancers including BC (Huang et al., 2015), papillary thyroid carcinoma (PTC) (Ning et al., 2016), oral squamous cell carcinoma (OSCC) (Wang et al., 2012) and gastric cancer (Li et al., 2013). Huang et al (Huang et al., 2015) found no relationship between the let-7 rs712 polymorphism and BC risk, but they determined its possible function in BC tumor metastasis that can be used as a new biomarker towards resistant tumor metastasis. In contrast, a meta-analysis by Ying et al (Ying et al., 2014) confirmed that allele T of rs712 enhances genetic risk of cancer in Chinese population.

To the best of our knowledge, no study has examined the influence of *KRAS* gene polymorphisms on BC susceptibility in an Iranian population. Accordingly, we aimed to investigate the potential relationship between *KRAS* variants (rs61764370 T/G and rs712 G/T) and BC risk in a sample of southeast Iranian women. Besides, we also evaluated the association of the *KRAS* variants with clinicopathological features of BC patients.

Materials and Methods {#sec1-2}
=====================

Study population {#sec2-1}
----------------

The present case-control study was done on 244 BC patients and 204 ages adjusted healthy women with no background of any malignancy. The clinicopathological characteristics of BC patients are shown in [Table 1](#T1){ref-type="table"}. The registration process and study design have been described in our previous investigations (Amininia et al., 2014; Rezaei et al., 2016; Sanaei et al., 2016). Ethical certificate for enrollment was taken from local Ethics Committee of Zahedan University of Medical Sciences (\#7082), and informed consent was acquired from all included individuals. We collected blood samples in EDTA-containing tubes from case and control subjects and extracted the DNA by salting out method as explained previously (Hashemi et al., 2013b).

###### 

Clinical and Pathological Characteristics of Breast Cancer Patients

  Characteristics                Cases n (%)
  ------------------------------ -------------
  Tumor Size (cm)                
    ≤2                           74 (30.3)
    \>2                          122 (50.0)
    Unknown                      48 (19.7)
  Nodal metastasis               
    No                           60 (24.6)
    Yes                          152 (62.3)
    Unknown                      32 (13.1)
  Grade                          
    I                            39 (16.0)
    II                           115 (47.1)
    III                          40 (16.4)
    IV                           1 (0.4)
    Unknown                      49 (20.1)
  Stage                          
    I                            38 (15.6)
    II                           85 (34.8)
    III                          68 (27.9)
    IV                           39 (16.0)
    Unknown                      14 (5.7)
  Histology                      
    Ductal carcinoma             158 (70.5)
    Other                        66 (29.5)
  Estrogen Receptor status       
    Positive                     137 (56.1)
    Negative                     81 (33.2)
    Unknown                      26 (10.7)
  Progesterone Receptor status   
    Positive                     133 (54.5)
    Negative                     84 (34.4)
    Unknown                      27 (11.1)
  HER2 status                    
    Positive                     117 (48.0)
    Negative                     113 (46.3)
    Unknown                      14 (5.7)

Genotyping Method {#sec2-2}
-----------------

We used polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method for identification of *KRAS* SNPs. For *KRAS* rs61764370, the forward and reverse primers were 5\`-GTGTCAGAGTCTCGCTCTTGTC-3\` and 5\`-AGACCACACTAGCACTACCTAAGGA-3\`, respectively. For *KRAS* rs712 the primers were 5\`-AAGGCATACTAGTACAAGTGGTAA-3\` and 5\`-TGTGTTCCCTCAATGTTTCAGT-3\`.

In each 0.20 ml PCR reaction tube, we mixed 1 μl of genomic DNA (\~100 ng/ml), 1 μl of each primer and 10 μl of 2X Prime Taq Premix (Genet Bio, Korea) in addition to 7 μl ddH2O. The PCR conditions were standardized as follows: 5 min preheating at 95°C, 30 cycles of 95°C for 30s, 62°C for rs712, and 58°C for rs61764370 for 30s, and 72 °C for 30s followed by a final extension step for 10 min at 72 °C. For rs61764370, the PCR product (10 μl) was digested using HinfI restriction enzyme (Thermo Scientific, Vilnius, Lithuania). The T allele was digested and produced 80, 135, 161 bp fragments, but the G allele produces 296 and 80-bp amplicons ([Figure 1](#F1){ref-type="fig"}).

![Photograph of the *KRAS* rs61764370 Polymorphism Using PCR-RFLP. The T allele was digested by HinfI restriction enzyme and produces 80-, 135-, and 161-bp fragments, but the G allele produces 296-and 80-bpfragments. M: DNA marker; Lanes 1, 2, 4, and 6: TT; Lanes 3, and 5:TG.](APJCP-18-1301-g001){#F1}

For *KRAS* rs712, 10 μl of PCR product was digested using TaqI (Thermo Scientific, Vilnius, Lithuania) restriction enzyme. Product size was 426-bp for T allele (undigested); G allele digested and produces 154-bp and 272-bp ([Figure 2](#F2){ref-type="fig"}). To verify the genotyping quality, we randomly re-genotyped 20% of the samples and the genotypic were 100% concordant.

![Photograph of the *KRASrs*712 Polymorphism Using PCR-RFLP. The G allele digested by TaqI restriction enzyme and produces 154-bp and 272-bp, however T allele undigested (426-bp). M: DNA marker; Lanes 1, 3, 4, 5, and 8, GT; Lane 2, TT; Lanes 6, and 7, GG.](APJCP-18-1301-g002){#F2}

Statistical analysis {#sec2-3}
--------------------

Statistical analyses were executed by SPSS 19.0 software package. Independent sample t-test and the χ2 test were applied for continuous and categorical data, respectively. The association between genotypes and BC were determined by calculating the odds ratio (OR) and 95% confidence intervals (95% CI) from logistic regression analyses. All reported p values are two-sided and took into account statistically significant if p was below 0.05. Besides, Hardy-Weinberg equilibrium (HWE) was calculated for both cases and controls.

Results {#sec1-3}
=======

The present study group included 244 BC patients with a mean age of 49.1 ±11.1 years and 204 healthy women with a mean age of 48.9 ±12.1 years. No significant difference was found between the groups regarding age (p=0.838). The HWE calculation indicated that both *KRAS* SNPs were in HWE in the control group (P\>0.05).

The genotype and allelic frequency of *KRAS* rs712 G\>T and rs61764370 T\>G polymorphisms are shown in [table 2](#T2){ref-type="table"}. Our findings indicated that rs61764370 T\>G heterozygote TG genotype vs TT was associated with higher risk of developing BC (TT vs GG+GT: OR=3.55, 95% CI=1.31-9.65, P=0.012). Similarly, in allele comparison G vs T, our analysis indicated that the G allele was a risk factor for BC (OR=3.44, 95%CI=1.28-9.29, P=0.013).

###### 

Association of *KRAS* Gene Polymorphisms (Rs712 G/T and Rs61764370 T/G) and the Risk of Breast Cancer

  Polymorphism      Case n (%)   Control n (%)   OR (95%CI)         p-value
  ----------------- ------------ --------------- ------------------ ---------
  rs61764370 T\>G                                                   
    TT              224 (91.8)   199 (97.5)      1                  \-
    TG              20 (8.2)     5 (2.5)         3.55 (1.31-9.65)   0.012
    GG              0 (0.0)      0 (0.0)         \-                 \-
  Allele                                                            
    T               468 (95.9)   403 (98.8)      1                  \-
    G               20 (4.1)     5 (1.2)         3.44 (1.28-9.29)   0.013
  rs712 G\>T                                                        
  Codominant                                                        
    GG              33 (13.5)    25 (12.3)       1                  \-
    GT              148 (60.7)   101 (49.5)      1.11 (0.62-1.98)   0.768
    TT              63 (25.8)    78 (38.2)       0.60 (0.33-1.07)   0.104
  Dominant                                                          
    GG              33 (13.5)    25 (12.3)       1                  \-
    GT+TT           211 (85.7)   179 (87.4)      0.51 (0.51-1.56)   0.893
  Recessive                                                         
    GG+GT           181 (74.2)   126 (61.8)      1                  \-
    TT              63 (25.8)    78 (38.2)       0.56 (0.38-0.84)   0.006
  Allele                                                            
    G               214 (43.9)   151 (37.0)      1                  \-
    T               274 (56.1)   257 (63.0)      0.75 (0.57-0.98)   0.041

With respect to rs712 G\>T variation, our results demonstrated that the rs712 G\>T variant was associated with a reduced risk of BC in recessive model (TT vs GG+GT: OR=0.56, 95% CI=0.38-0.84, P=0.006) as well as in allele comparison (T vs G: OR=0.75, 95% CI=0.57-0.98, P=0.041).

However, no significant association between clinical characteristics of BC patients including age, histological type, tumor size, stage, grade, ER, PgR and HER2 and the studied *KRAS* gene polymorphisms was observed (P\>0.05, data not shown).

Discussion {#sec1-4}
==========

The current study confirmed the relationship of *KRAS* gene polymorphisms and the risk of BC in an Iranian population. According to our results, the rs61764370 TG vs TT and G vs T allele were risk factors for BC. However, the rs712 TT vs GG+GT genotype and T vs G allele reduced the risk of BC with OR of 0.56 and 0.75, respectively.

In accordance with our findings, Pilarski et al., (2012) indicated that *KRAS*rs61764370 polymorphism was associated with the risk of double primary breast and ovarian cancer. Another study Paranjape et al., (2011) showed the *KRAS* variant is a risk factor for triple negative breast cancer in premenopausal women (OR 2.31, 95% CI 1.26-4.22) highlighting its role as a genetic marker. On the other hand, Uvirova et al., (2015) have found no association between *KRAS* rs61764370 variant and risk of BC risk, although they suggested that *KRAS* rs61764370 TG genotype could affect the HER2 gene expression profile. Cerne et al., (2012) also found no proof of relationship of *KRAS* rs61764370 variant with risk of sporadic and familial breast cancer which supports the findings of a meta-analysis by Zhang et al., (2016) who summarized that *KRAS* genotype GT/GG of rs61764370 was not related to the risk of breast, ovarian, non.-small cell lung cancer, colorectal, or head-neck carcinoma in Caucasian population.

Let-7 appears to play key roles in the BC advancement, because breast-tumour-initiating cells demonstrated markedly low levels of let-7; therefore, reintroduction of let-7 inhibits these putative BC stem cells by control of their self-renewal and ability to differentiate. Recent proof also suggests a central role for the let-7 miRNA family in progression of BC via altered expression of *KRAS*, an infrequent target of activating mutations in breast tumors (Kumar and Swanton, 2011). LCS6 in the *KRAS* 3'-UTR mRNA causes an increase in expression of *KRAS* in vitro and a reduction in let-7 levels in vivo (Chin et al., 2008). In contrast, Crowley et al., (2014) indicated that targeted knock-in of the polymorphism rs61764370 was not associated with *KRAS* levels but decreased let-7 expression. The *KRAS* LCS6 variant is rather infrequent, and extremely rare in East Asians and in Native Americans, and so uncommon in Africans with a minor allele frequency of 7% in the European populations (Chin et al., 2008). Similarly, in our study, the *KRAS* LCS6 variant allele was 4.1% in BC patients and 1.2% in healthy women.

With respect to rs712, our findings indicated that the rs712 TT vs GG+GT genotype in the recessive model and T vs G allele were protective factors against BC. Compared to our findings, Ning et al., (2016) found a considerable difference in both allelic and genotypic genotypes incidence for rs712 between PTC patients and control subjects. Dai et al., (2016) also demonstrated that TT genotype and T allele of rs712 were increased the risk of CRC. A meta-analysis by Zhao et al., (2015) concluded that allele T, genotype TT and allele T carrier (GT/TT) of rs712 may increase cancer risk in Chinese population, and potentially is capable of being used as a genetic factor for assessment of cancer risk. However, Huang et al., (2015) found no association between the let-7 rs712 polymorphism and BC risk, which supports the results of two studies performed on nasopharyngeal carcinoma (Pan et al., 2014) and PTC (Jin et al., 2014).

There are some limitations in the present study, one of which is investigating only two SNPs of the *KRAS* gene. Second limitation is lacking the information concerning the known risk factors for BC (e.g., parity, oral contraceptive or hormone therapy use, breast-feeding, smoking and alcohol intake). So, we were unable to determine the interaction between the variants and environmental factors.

Overall, our study provided the evidence regarding the implication of *KRAS* polymorphisms, rs61764370 and rs712, in developing breast carcinoma with lack of any relationship with clinicopathological features of the patients. The *KRAS* rs61764370 variant increased the BC risk, but the rs712 variant was a protective factor against BC in the studied Iranian population. More studies on larger sample sizes with different races are warranted to confirm our findings.
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